Analyst consensus rating
Verrica Pharmaceuticals Analyst Rating: none
VRCA is rated none by 5 analysts with a $14.80 target. As of 2026-08-24.
Direct answer
Verrica Pharmaceuticals's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.80.
Forecast evidence checked August 24, 2026.
Get free Verrica Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.82
- Average price target
- $14.80
- High price target
- $20.00
- Low price target
- $10.00
- Low target gap
- +107.5%
- Target upside
- +207.1%
- High target gap
- +314.9%
- Target range width
- 207.5%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Verrica Pharmaceuticals?
Verrica Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $14.80.
How far are Verrica Pharmaceuticals's low and high targets from the recorded price?
The low target implies +107.5%, while the high target implies +314.9%.
How many analysts are included in Verrica Pharmaceuticals's consensus?
The verified consensus includes 5 analysts.
How is Verrica Pharmaceuticals's target upside or downside calculated?
The average target of $14.80 is divided by the recorded price of $4.82, then one is subtracted to produce +207.1%. This does not guarantee a future return.
When was Verrica Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.